$80.14
-2.25-2.73%
마지막 업데이트: Oct 16, 4:00 PM
$82.00
-0.39-0.47%
Benzinga
Benzinga
Benzinga
금요일, 10월 16
Benzinga
© 2026 Benzinga | All Rights Reserved
Mirum Pharmaceuticals (MIRM) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Mirum Pharmaceuticals (MIRM)는 8월 5, 2026에 fiscal year 2026에 대한 가이던스를 마지막으로 발표했습니다. 회사는 해당 기간의 매출을 $680M - $700M 범위로 예상했습니다.
이전 가이던스와 비교하여 Mirum Pharmaceuticals는 매출 전망치를 이전 범위인 상향 조정됨에서 $660M - $680M로 상향 조정했습니다.
Mirum Pharmaceuticals은 13과 11월 9, 2022 사이에 8월 5, 2026개의 지침 업데이트를 발표했습니다. During this period, the company raised its outlook 9 times and lowered it 1 time, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.80 | $-0.36 | $0.04 | $-0.14 |
| Actual | $-0.80 | $-0.50 | $-0.12 | $0.05 |
| Surprise | 0.00% | -38.9% | -400.0% | +135.7% |
| Revenue | ||||
| Estimate | $165.5M | $148.2M | $141.6M | $131.1M |
| Actual | $176.2M | $159.9M | $148.9M | $133.0M |
| Surprise | +6.46% | +7.91% | +5.19% | +1.49% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.45 | $-0.39 | $-0.17 | $-0.16 |
| Revenue | ||||
| Consensus | $177.5M | $182.8M | — | — |
| 회계 분기 | 보고된 날짜 | 실제 EPS | 예상 EPS | 놀라다 % |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $-0.80 | $-0.80 | 0.00 % |
| Q1 | May 6, 2026 | $-0.50 | $-0.36 | -38.9 % |
| Q4 | Feb 25, 2026 | $-0.12 | $0.04 | -400.0 % |
| Q3 | Nov 4, 2025 | $0.05 | $-0.14 | 135.7 % |
| 회계 분기 | 보고된 날짜 | 실제 수익 | 예상 수익 | 놀라다 % |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $176.24M | $165.55M | 6.46 % |
| Q1 | May 6, 2026 | $159.88M | $148.17M | 7.91 % |
| Q4 | Feb 25, 2026 | $148.93M | $141.58M | 5.19 % |
| Q3 | Nov 4, 2025 | $133.01M | $131.06M | 1.49 % |